Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

This study has been completed.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: May 28, 2013
Last updated: September 22, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2016
  Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)